Compare Brigit Biofarmaka Teknologi Tbk. (OBAT) vs Reksa Dana Indeks Premier ETF FTSE Indonesia ESG (XIFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brigit Biofarmaka Teknologi Tbk. vs Reksa Dana Indeks Premier ETF FTSE Indonesia ESG — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp240 (market cap 166.01B, 324K 24h volume), while Reksa Dana Indeks Premier ETF FTSE Indonesia ESG trades at Rp95 (market cap 31.23B, 9.4K 24h volume). The key difference: Brigit Biofarmaka Teknologi Tbk. is far larger — about 5.3× Reksa Dana Indeks Premier ETF FTSE Indonesia ESG's market cap, and Brigit Biofarmaka Teknologi Tbk. is more actively traded (324K versus 9.4K). Which is the better fit depends on your goals.
| OBAT | XIFE | |
|---|---|---|
Market Cap | 166.01B | 31.23B |
Volume | 324K | 9.4K |
Lot | 3.24K | 94 |
Turnover | 77.68M | 893K |
Average Price | 239.75 | 95 |
Value | 77.68M | 893K |
Indicative Equilibrium Price | 240 | — |
Indicative Equilibrium Volume | 1 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →
